Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A*01 negative rhesus macaques.

Published

Journal Article

Previously, replicating adenovirus type 5 host range (Ad5hr)-HIV/SIV recombinant priming in combination with SIV envelope boosting, resulted in significant, durable protection in 39% of rhesus macaques after SIVmac251 challenge. Both Env-specific antibody mediating ADCC, and cellular immunity correlated with protection. Here we evaluate the relative immunogenicities of novel HIV proteins and their contribution to protection in a SHIV89.6P model. All groups were primed with Ad-HIVenv89.6P, SIVgag239, and SIVnef239 recombinants. One group was not boosted, one received HIV89.6Pgp140DeltaCFI protein, and one a novel HIV-1 poly-peptide "peptomer". The HIV89.6Pgp140DeltaCFI protein in adjuvant strongly boosted Env-specific antibody and memory T cell responses in blood and tissue, resulting in significant reductions in acute and set point viremia. Macaques not boosted, showed a significant reduction in set point viremia, a full 32 weeks after the last Ad priming immunization. The HIV peptomer-boosted group showed a trend toward chronic viremia reduction, but was not protected.

Full Text

Duke Authors

Cited Authors

  • Patterson, LJ; Beal, J; Demberg, T; Florese, RH; Malkevich, N; Venzon, D; Aldrich, K; Richardson, E; Kalyanaraman, VS; Kalisz, I; Lee, EM; Montefiori, DC; Robey, FA; Robert-Guroff, M

Published Date

  • May 10, 2008

Published In

Volume / Issue

  • 374 / 2

Start / End Page

  • 322 - 337

PubMed ID

  • 18252262

Pubmed Central ID

  • 18252262

International Standard Serial Number (ISSN)

  • 0042-6822

Digital Object Identifier (DOI)

  • 10.1016/j.virol.2007.12.037

Language

  • eng

Conference Location

  • United States